Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy
Biotech Stock Intel
Catalyst CalendarPDUFA CalendarMover SignalsCompany Screener
Home/Stocks/SYRE/Catalyst
Phase 2Data readout

SPY003

Ulcerative colitis

SYRESpyre Therapeutics Inc
Expected catalystSeptember 30, 2026Company guidance: Sep 30, 2026

Catalyst overview

Event details

Drug or asset
SPY003
Development stage
Phase 2
Event type
Data readout
Indication
Ulcerative colitis
Research signalsHigh management interest

Research summary

What is being tracked?

This catalyst tracks a Phase 2 data readout for SPY003 in Ulcerative colitis. The expected timing is based on the latest available company guidance and may change.

Development notes

03/16/26:- SKYLINE UC platform enrolling ahead of schedule; Part A readouts begin Q2 2026. 04/13/26:- SKYLINE Part A induction data expected Q3 2026. Part B induction data remains on track for 2027. 05/05/26:- SPY003 Phase 1 safety and PK data supportive; ECCO 2026 results highlighted. SKYLINE Part A induction data Q3 2026. 06/03/26:- SKYLINE Part A now fully enrolled. Part A induction data remains expected in Q3 2026. 08/04/26:- SKYLINE SPY003 Part A data expected September 2026; Part B data 2027.

Verification

Primary source

Confirm timing and program details against the company announcement or filing.

Open source

More from SYRE

Related pipeline programs

Phase 2

SPY001 (α4β7)

Crohns disease, Inflammatory bowel disease

View company pipeline
Phase 2

SPY002 (SPY002-091) (TL1A)

Inflammatory bowel disease, Ulcerative colitis

View company pipeline
Phase 2

SPY072 (SPY002-072)

Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA)

View company pipeline
Phase 2

SPY072 (SPY002-072) (TL1A Antibody)

Hidradenitis Suppurativa

View company pipeline

Company

Spyre Therapeutics Inc

SYRE · NasdaqGS
Industry
Biotechnology
Pipeline assets
6
View SYRE research

BioPharma Pro

Track every date change

Watchlists, source history and catalyst alerts will be available with Pro.

Start free

Updated Aug 23, 2026. Dates can change; this is not investment advice.

Disclaimer: Biotech Stock Intel is an independent research platform. Information is provided for informational purposes only and is not investment or medical advice. Always verify catalyst dates against primary sources and conduct your own research.
Biotech Stock Intel© 2026 Biotech Stock Intel
AboutMethodologyTermsPrivacy